Redeye has a positive view on the new agreement with Region Stockholm. We have expected agreements like this to be concluded following the NHS deal in the UK. These kinds of deals send strong signals about the strength of the product. In addition, we continue to have a favorable view of Lifeclean and the long-term possibilities. Therefore, we reiterate our base case value of SEK 16 per share.